Balanced news tone
News Sentiment
LFCR sentiment intelligence
Lifecore Biomedical Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
47
Balanced news tone
51 relevant articles
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-6.7% over one week, -15.8% over four weeks, trend inactive, and below fair value.
New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
76/100 classification
One-week reaction
-6.7%
Price reacting lower
Trend fit
Trend inactive
-15.8% over four weeks
Fair value
-28.6%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
36
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years
Lifecore Biomedical (NASDAQ: LFCR) has granted 3,500 restricted stock units (RSUs) to a newly hired employee as an inducement award, in accordance with Nasdaq Listing Rule 5635(c)(4). These RSUs will vest on the third anniversary of the July 13, 2026 grant date, contingent on con
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:40
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced the grant of a restricted stock unit (RSU) award for 3,500 shares of its common stock to a newly hired employee. This grant, made under Lifecore’s Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), serv
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 19:40
- Source
- GlobeNewswire
Market source
Direct company coverage
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 13:11
- Source
- Market source
Quartr
Direct company coverage
Lifecore Biomedical (LFCR) Proxy filing Summary
Lifecore Biomedical's 2026 annual meeting, scheduled for June 4, 2026, will address four key proposals including the election of nine directors, ratification of KPMG LLP as auditor, advisory approval of executive compensation, and the 2026 Stock Incentive Plan. Holders of Common
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 10:14
- Source
- Quartr
Quartr
Direct company coverage
Lifecore Biomedical (LFCR) Q2 2024 earnings summary
Lifecore Biomedical (LFCR) reported strong Q2 FY2024 earnings, with total revenues up 38% year-over-year to $30.2M and a net income of $14.2M, compared to a net loss in the prior year. The company has transitioned to a pure-play CDMO, focusing on sterile injectable pharmaceutical
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 14 Jul 2026 07:16
- Source
- Quartr
Quartr
Direct company coverage
Lifecore Biomedical (LFCR) Q1 2026 earnings summary
Lifecore Biomedical reported its Q1 2026 earnings with revenue down 34% year-over-year to $23.2 million and a net loss of $15.0 million. Despite the decline, the company saw a 52% reduction in operating expenses and signed three new commercial site transfer programs. Lifecore rea
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 07:14
- Source
- Quartr
Quartr
Direct company coverage
Lifecore Biomedical (LFCR) Q3 2024 earnings summary
Lifecore Biomedical (LFCR) reported a strong Q3 FY24, with total revenues rising 35% year-over-year to $35.7M and net income reaching $15.6M, a significant improvement from a net loss in the prior year. The company has transitioned to a pure-play CDMO focusing on sterile injectab
- Tone
- Positive 73/100
- Event
- Earnings
- Published
- 14 Jul 2026 02:14
- Source
- Quartr
Moomoo
Direct company coverage
Lifecore Biomedical (LFCR) Stock Forum and Discussion
This document appears to be a placeholder or an incomplete article about Lifecore Biomedical (LFCR). It is titled "Lifecore Biomedical (LFCR) Stock Forum and Discussion" but contains no substantive content.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 18:10
- Source
- Moomoo
Stock Titan
Direct company coverage
[SCHEDULE 13D/A] LIFECORE BIOMEDICAL, INC. \DE\ Amended Major Shareholder Report
This SCHEDULE 13D/A filing for Lifecore Biomedical, Inc. (LFCR) details an amended major shareholder report by 22NW Fund, LP and related entities. It specifies that 22NW Fund, LP beneficially owns 2,712,472 shares, representing 6.74% of the outstanding common stock, including con
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 03 Jul 2026 03:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Legion Partners (LFCR) reports 17.1% stake and seeks cash redemption of Lifecore preferred
Legion Partners and its affiliates have reported a significant 17.1% stake in Lifecore Biomedical (LFCR) through a recent SEC filing. The filing indicates beneficial ownership of up to 6,794,595 common shares on an as-converted basis, including shares from immediately convertible
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 03 Jul 2026 03:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Lifecore Biomedical (NASDAQ: LFCR) gets $52.1M preferred redemption requests
Lifecore Biomedical has received redemption notices for all outstanding shares of its Series A Redeemable Convertible Preferred Stock, requiring a $52.1 million cash redemption by December 28, 2026. The company's current liquidity of $38.1 million is less than the redemption amou
- Tone
- Negative 31/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 21:10
- Source
- Stock Titan
TradingView
Direct company coverage
Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026
Lifecore Biomedical announced a $52.1 million redemption obligation due December 28, 2026, stemming from notices to redeem all 49,263 shares of its Series A preferred stock. The total payout includes a liquidation value of approximately $50.2 million and $0.9 million in accrued d
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 02 Jul 2026 21:10
- Source
- TradingView
Simply Wall Street
Direct company coverage
Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?
Lifecore Biomedical, Inc. (LFCR) has seen a significant price increase but is currently overvalued by about 30% according to Simply Wall St's valuation model, trading at US$4.96 against an intrinsic value of $3.82. The company is expected to have highly negative earnings growth,
- Tone
- Negative 36/100
- Event
- Earnings
- Published
- 30 Jun 2026 10:10
- Source
- Simply Wall Street
Market source
Direct company coverage
Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Market source
The National Law Review
Direct company coverage
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing at Lifecore Biomedical, Inc. (LFCR). The firm is encouraging investors who purchased Lifecore securities before October 7, 2020, and still hold them, to contact them for more info
- Tone
- Negative 27/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 14:40
- Source
- The National Law Review
TradingView
Direct company coverage
Price to book forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR
This article presents the "Price to book forward" financial metric for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a brief data point provided by TradingView, with no additional analytical content.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 13:43
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR
This page provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), focusing on its enterprise value to revenue forward. The content is hosted on TradingView, a financial platform offering various market data and analysis tools. It appears to be a snapshot or a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 06:39
- Source
- TradingView
The National Law Review
Direct company coverage
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) who bought securities prior to October 7, 2020, and still hold them. The investigation aims to determine if Lifecore's officers and/or director
- Tone
- Negative 18/100
- Event
- Regulatory and legal
- Published
- 28 Jun 2026 06:11
- Source
- The National Law Review
TradingView
Direct company coverage
Price to sales forward of Lifecore Biomedical, Inc. – SWB:LDE
The article displays the "Price to sales forward" metric for Lifecore Biomedical, Inc. (SWB:LDE) on the Stuttgart Stock Exchange. It indicates that the market is closed with no trades recorded and provides financial data and other market information.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 04:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Lifecore Biomedical, Inc. – LSX:899376
This article provides financial information for Lifecore Biomedical, Inc. (LSX:899376), specifically focusing on its price-to-sales forward metric. The data is presented via TradingView, which aggregates market and reference data from various sources like ICE Data Services and Fa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 21:10
- Source
- TradingView
TradingView
Direct company coverage
Lifecore Biomedical, Inc. Actuals & Estimates (NASDAQ:LFCR)
This article provides an overview of Lifecore Biomedical, Inc. (NASDAQ: LFCR) stock, including its current price, performance trends, and analyst forecasts. It details financial actuals and estimates for income, balance sheet, and cash flow, along with frequently asked questions
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 27 Jun 2026 19:10
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR
This article provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), specifically focusing on its forward price-to-earnings ratio. It seems to be a placeholder or snapshot from a financial platform, showing that there are no current trades and directing users
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 09:39
- Source
- TradingView
TradingView
Direct company coverage
LFCR Forecast — Price Target — Prediction for 2027
This article provides an overview of Lifecore Biomedical, Inc. (LFCR) stock, including its current price, analyst forecasts, and financial data. Analysts predict a maximum price of $9.00 and a minimum of $5.00 for LFCR. The article also covers historical price performance, volati
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Jun 2026 01:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR
This article displays the forward Enterprise Value to EBIT for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a financial data point presented by TradingView, indicating the company's valuation relative to its expected operating earnings. The information is provided without furt
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 17:40
- Source
- TradingView
TradingView
Direct company coverage
Lifecore Biomedical, Inc. Actuals & Estimates (BOATS:LFCR)
This article provides financial actuals and estimates for Lifecore Biomedical, Inc. (LFCR) on the BOATS exchange, including analyst forecasts, historical stock prices, and upcoming earnings dates. It details the company's past quarterly earnings and revenue, noting that LFCR does
- Tone
- Negative 40/100
- Event
- Earnings
- Published
- 26 Jun 2026 12:39
- Source
- TradingView
TradingView
Direct company coverage
Lifecore Biomedical, Inc. Actuals & Estimates (GETTEX:LDE)
Lifecore Biomedical, Inc. (GETTEX:LDE) stock is currently trading at 4.58 EUR, having decreased by 4.98% in the past 24 hours. The company's market capitalization is 177.81 million EUR, and analysts have a price target range of 4.31 EUR to 7.77 EUR for the stock. Lifecore is set
- Tone
- Negative 38/100
- Event
- Analyst action
- Published
- 26 Jun 2026 12:11
- Source
- TradingView
TradingView
Direct company coverage
LDE Forecast — Price Target — Prediction for 2027
This article provides a forecast for Lifecore Biomedical, Inc. (LDE) stock, including analyst price targets and ratings. It details recent stock performance, financial metrics like EPS and revenue, and answers common questions about the company's stock, market capitalization, ear
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 07:10
- Source
- TradingView
TradingKey
Direct company coverage
Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Lifecore Biomedical Inc (LFCR) focusing on its stock resistance, support levels, and various technical indicators. The current price momentum score is 8.18, suggesting the stock is suitable for range-bound swing trading between $5.07
- Tone
- Negative 20/100
- Event
- Market update
- Published
- 23 Jun 2026 00:10
- Source
- TradingKey
TradingKey
Direct company coverage
Lifecore Biomedical Inc (LFCR) Institutional Confidence
The article details the institutional confidence level in Lifecore Biomedical Inc (LFCR), noting its score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion has increased to 81.48%, with ETHSX being the largest sharehol
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 22 Jun 2026 23:10
- Source
- TradingKey
Stock Traders Daily
Direct company coverage
How (LFCR) Movements Inform Risk Allocation Models
This article provides an in-depth analysis of Lifecore Biomedical Inc. (LFCR) using AI models, highlighting a 66.5:1 risk-reward setup targeting a 24.8% gain. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, o
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 04:10
- Source
- Stock Traders Daily